A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy

Virology

Volumn 501, Issue , 2017, Pages 115-118

  Hu, Shuang ^a   Neff, Charles Preston ^a,b   Kumar, Dipu Mohan ^a   Habu, Yuichiro ^a   Akkina, Sarah R ^a,c   Seki, Takahiro ^a,d   Akkina, Ramesh ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d SHIONOGI AND CO LTD   (Japan)

Author keywords

Animal model for HIV 2 infection and therapy; Combinatorial ART for HIV; HIV 2 therapeutic testing in humanized mice; Humanized mice for HIV research; Single pill triple drug therapy fot HIV 2; Triple drug Triumeq therapy for HIV

Indexed keywords

ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DOLUTEGRAVIR; FUSED HETEROCYCLIC RINGS; LAMIVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL LOSS; CONTROLLED STUDY; DRUG EFFICACY; FETUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MOUSE; NEWBORN; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; T CELL DEPLETION; VIREMIA; VIRUS LOAD; VIRUS PATHOGENESIS; ANIMAL; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 2; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-2; HUMANS; LAMIVUDINE; MICE; MICE, INBRED BALB C;

EID: 84999143752     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2016.11.013     Document Type: Article

References (27)

1. Akkina, R., New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435 (2013), 14–28.
2. Akkina, R.K., Rosenblatt, J.D., Campbell, A.G., Chen, I.S., Zack, J.A., Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood 84 (1994), 1393–1398.
3. Arts, E.J., Hazuda, D.J., HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med., 2, 2012, a007161.
4. Berges, B.K., Akkina, S.R., Folkvord, J.M., Connick, E., Akkina, R., Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice. Virology 373 (2008), 342–351.
5. Berges, B.K., Akkina, S.R., Remling, L., Akkina, R., Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology 397 (2010), 100–103.
6. Berges, B.K., Wheat, W.H., Palmer, B.E., Connick, E., Akkina, R., HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology, 3, 2006, 76.
7. Boyer, P.L., Clark, P.K., Hughes, S.H., HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors. J. Virol. 86 (2012), 5885–5894.
8. Buggert, M., Frederiksen, J., Lund, O., Betts, M.R., Biague, A., Nielsen, M., Tauriainen, J., Norrgren, H., Medstrand, P., Karlsson, A.C., Jansson, M., CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection. AIDS, 2016.
9. Campbell-Yesufu, O.T., Gandhi, R.T., Update on human immunodeficiency virus (HIV)-2 infection. Clin. Infect. Dis. 52 (2011), 780–787.
10. Cavaco-Silva, J., Abecasis, A., Miranda, A.C., Pocas, J., Narciso, J., Aguas, M.J., Maltez, F., Almeida, I., Germano, I., Diniz, A., Goncalves Mde, F., Gomes, P., Cunha, C., Camacho, R.J., HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. PloS One, 9, 2014, e92747.
11. Damond, F., Benard, A., Balotta, C., Boni, J., Cotten, M., Duque, V., Ferns, B., Garson, J., Gomes, P., Goncalves, F., Gottlieb, G., Kupfer, B., Ruelle, J., Rodes, B., Soriano, V., Wainberg, M., Taieb, A., Matheron, S., Chene, G., Brun-Vezinet, F., An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J. Clin. Microbiol. 49 (2011), 3491–3497.
12. de Silva, T.I., Cotten, M., Rowland-Jones, S.L., HIV-2: the forgotten AIDS virus. Trends Microbiol. 16 (2008), 588–595.
13. Denton, P.W., Garcia, J.V., Humanized mouse models of HIV infection. AIDS Rev. 13 (2011), 135–148.
14. Ekouevi, D.K., Tchounga, B.K., Coffie, P.A., Tegbe, J., Anderson, A.M., Gottlieb, G.S., Vitoria, M., Dabis, F., Eholie, S.P., Antiretroviral therapy response among HIV-2 infected patients: a systematic review. BMC Infect. Dis., 14, 2014, 461.
15. Greig, S.L., Deeks, E.D., Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs 75 (2015), 503–514.
16. Hu, S., Mohan Kumar, D., Sax, C., Schuler, C., Akkina, R., Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses. Virology 488 (2016), 162–168.
17. Kanki, P.J., Travers, K.U., S, M.B., Hsieh, C.C., Marlink, R.G., Gueye, N.A., Siby, T., Thior, I., Hernandez-Avila, M., Sankale, J.L., et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343 (1994), 943–946.
18. Marlink, R., Kanki, P., Thior, I., Travers, K., Eisen, G., Siby, T., Traore, I., Hsieh, C.C., Dia, M.C., Gueye, E.H., et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265 (1994), 1587–1590.
19. Menendez-Arias, L., Alvarez, M., Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antivir. Res. 102 (2014), 70–86.
20. Nyamweya, S., Hegedus, A., Jaye, A., Rowland-Jones, S., Flanagan, K.L., Macallan, D.C., Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev. Med. Virol. 23 (2013), 221–240.
21. Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. FASEB J. 22 (2008), 659–661.
22. Reeves, J.D., Doms, R.W., Human immunodeficiency virus type 2. J. Gen. Virol. 83 (2002), 1253–1265.
23. Ren, J., Bird, L.E., Chamberlain, P.P., Stewart-Jones, G.B., Stuart, D.I., Stammers, D.K., Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 99 (2002), 14410–14415.
24. Rodes, B., Toro, C., Jimenez, V., Soriano, V., Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. Clin. Infect. Dis. 41 (2005), e19–e21.
25. Stevenson, M., HIV-1 pathogenesis. Nat. Med. 9 (2003), 853–860.
26. Thiebaut, R., Matheron, S., Taieb, A., Brun-Vezinet, F., Chene, G., Autran, B., Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. AIDS 25 (2011), 865–867.
27. Trevino, A., Cabezas, T., Lozano, A.B., Garcia-Delgado, R., Force, L., Fernandez-Montero, J.M., Mendoza, C., Caballero, E., Soriano, V., Dolutegravir for the treatment of HIV-2 infection. J. Clin. Virol. 64 (2015), 12–15.